395 related articles for article (PubMed ID: 16972901)
21. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
22. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.
Oizumi S; Deyev V; Yamazaki K; Schreiber T; Strbo N; Rosenblatt J; Podack ER
J Immunother; 2008 May; 31(4):394-401. PubMed ID: 18391756
[TBL] [Abstract][Full Text] [Related]
23. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
24. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
25. Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy".
Beyer M; Karbach J; Mallmann MR; Zander T; Eggle D; Classen S; Debey-Pascher S; Famulok M; Jäger E; Schultze JL
Cancer Res; 2009 May; 69(10):4346-54. PubMed ID: 19435912
[TBL] [Abstract][Full Text] [Related]
26. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
[TBL] [Abstract][Full Text] [Related]
27. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.
de Souza AP; Bonorino C
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
29. Differential modulation of CNS-specific effector and regulatory T cells during tolerance induction by recombinant invariant chains in vivo.
Lange C; Doster H; Steinbach K; Kalbacher H; Scholl M; Melms A; Bischof F
Brain Behav Immun; 2009 Aug; 23(6):861-7. PubMed ID: 19362139
[TBL] [Abstract][Full Text] [Related]
30. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
31. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
32. Making and circumventing tolerance to cancer.
Kammertoens T; Blankenstein T
Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
[TBL] [Abstract][Full Text] [Related]
33. Using signaling pathways to overcome immune tolerance to tumors.
Engleman EG; Brody J; Soares L
Sci STKE; 2004 Jul; 2004(241):pe28. PubMed ID: 15252217
[TBL] [Abstract][Full Text] [Related]
34. New insights into the role of T cells in the vicious cycle of bone metastases.
Fournier PG; Chirgwin JM; Guise TA
Curr Opin Rheumatol; 2006 Jul; 18(4):396-404. PubMed ID: 16763461
[TBL] [Abstract][Full Text] [Related]
35. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
36. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
37. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
38. Cancer and immune response: old and new evidence for future challenges.
de la Cruz-Merino L; Grande-Pulido E; Albero-Tamarit A; Codes-Manuel de Villena ME
Oncologist; 2008 Dec; 13(12):1246-54. PubMed ID: 19056856
[TBL] [Abstract][Full Text] [Related]
39. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
Liakou CI; Narayanan S; Ng Tang D; Logothetis CJ; Sharma P
Cancer Immun; 2007 Jun; 7():10. PubMed ID: 17591743
[TBL] [Abstract][Full Text] [Related]
40. Suppression of T cell responses in the tumor microenvironment.
Frey AB
Vaccine; 2015 Dec; 33(51):7393-7400. PubMed ID: 26403368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
